Lashay et al - Intravitreal TA on Visual Acuity & MT Iranian Journal of Ophthalmology - Volume 19, Number 2, 2006
|
|
- Russell Tyler
- 5 years ago
- Views:
Transcription
1 Effect of Intravitreal Triamcinolone Acetonide on Visual Acuity and Macular Thickness in Macular Edema Associated with Nonischemic Central Retinal Vein Occlusion Alireza Lashay, MD 1, Haj-Mohammad Jalili, MD 2, Mehdi Nili-Ahmadabadi, MD 3 Ahmad Mirshahi, MD 3, Houshang Faghihi, MD 3, Seyed-Ali Tabatabaei, MD 4 Mohammad Riazi-Esfahani, MD 3, Reza Karkhaneh, MD 1, Mohammad-Sadegh Farahvash, MD 3 Ahmad Javadian, MD 1, Hormoz Chams, MD 1 Morteza Movasat, MD 3, Zahra Aalami-Harandi, MD 3 Abstract Purpose: To evaluate the effectiveness of intravitreal triamcinolone acetonide on visual acuity and macular thickness using optical coherence tomography in macular edema associated with nonischemic central retinal vein occlusion (CRVO). Design: A prospective interventional case series. Patients & Methods: Twenty eyes of 25 patients with nonischemic CRVO and macular edema with visual acuity of less than or equal to 0.4 logarithm of minimum angle of resolution (logmar) received 4 mg intravitreal triamcinolone acetonide after baseline examination which included measurement of best corrected visual acuity (BCVA) and intraocular pressure, slit lamp examination, fluorescein angiography, and optical coherence tomography (OCT) of macula. The main outcome measures were visual acuity after 1, 3, 6, and 9 months and 1-mm central macular thickness change at 3 months after injection. Results: Mean duration of symptoms before injection was (83.72±57.60 days). Mean visual acuity significantly improved from baseline 1.34±0.71 ( 20 / 400 ) to 0.67±0.42 ( 20 / 100 ), P=0.000, 0.61±0.42 ( 20 / 80 ), P=0.000, and 0.90±0.62 ( 20 / 160 ), P=0.004, at 1, 3, 6 months, respectively, but decreased to 1.43±0.76 ( 20 / 600 ), P=0.188 at 9 months. A 42.85% reduction observed in mean baseline 1-mm central macular thickness ± µm to (362.56± µm, P=0.000) at 3 months. Conclusion: Intravitreal triamcinolone acetonide can significantly be effective in reducing macular edema and improving visual acuity in nonischemic CRVO at least in short term but it is necessary to investigate the risks and benefits of this option with a control group. Key words: Intravitreal Triamcinolone Acetonide, Central Retinal Vein Occlusion, Macular Edema, Optical Coherence Tomography. Iranian Journal of Ophthalmology 2006; 19(2): Professor of Ophthalmology, Farabi Eye Hospital, Tehran University of Medical 2. Resident in Ophthalmology, Farabi Eye Hospital, Tehran University of Medical 3. Associate Prof. of Ophthalmology, Farabi Eye Hospital, Tehran University of Medical 4. Assistant Prof. of Ophthalmology, Farabi Eye Hospital, Tehran University of Medical 5. Professor of Ophthalmology, Farabi Eye Hospital, Tehran University of Medical Received: February 23, 2006 Accepted: May 25, 2006 (With Cooperation of Eye Research Center, Farabi Eye Hospital, Tehran University of Medical ) 6 Correspondence to: HM Jalili, MD Tehran, Farabi Eye Hospital Tel: jaliliha@razi.tums.ac.ir
2 Introduction Retinal vein occlusion is the second most common retinal vascular disorder after diabetic retinopathy. 1 Central retinal vein occlusion (CRVO) is one of the most common retinal vascular diseases that can be associated with severe irreversible visual loss and with improvement of vision in only 20% of cases. 1 Macular edema is a common cause of visual loss after central retinal vein occlusion. 2,3 It results from accumulation of fluid in the region distal to the thrombosis at the lamina cribrosa in CRVO, 4 secondary to hydrostatic stress and ischemia. 5 Hypoxia causes upregulation of vascular endothelial growth factor (VEGF), which is normally either absent or present in trace quantities in normal retina. Presence of VEGF in CRVO increases capillary permeability. 6 Intravitreal corticosteroids may stabilize leaky vascular endothelium and reduce the extracellular fluid accumulation, that cause macular edema, probably by downregulating VEGF. 7,8 It may act by inhibiting factors such as prostaglandins and interleukins that are inflammatory mediators implicated in the pathogenesis of macular edema. 9,10 A few studies on patients with CRVO have suggested that intravitreal corticosteroid reduces macular edema and improve visual acuity (VA). 11,12,14-17 In this prospective study we treated patients with macular edema due to CRVO, with 4 mg intravitreal triamcinolone acetonide in order to determine its effects on VA and macular thickness. Patients and Methods This study was a prospective interventional case series performed following the tenets of Declaration of Helsinki, after approval by the Institutional Review Board. Twenty five eyes of 25 patients with nonischemic CRVO and macular edema were enrolled. Diagnosis of CRVO was defined by 4 quadrant retinal hemorrhage, venous tortuosity, optic disc and macular edema. A patient was considered to have a nonischemic CRVO if there was no relative afferent pupillary defect (RAPD), no rubeosis iridis, and capillary nonperfusion on fluorescein angiography (FA) less than 10 disc areas. Patients with nonischemic CRVO and macular edema with at least one month duration of 7 symptoms, BCVA 0.4 logarithm angle of resolution (logmar) ( 20 / 50 ), clear media and intraocular pressure (IOP) lower than 22 mm Hg were enrolled in this study. Exclusion criteria were ischemic CRVO, one-eye patient, other ocular disease that may prominently affect VA (cataract, age-related macular degeneration, diabetic retinopathy) and history or confirmed diagnosis of glaucoma or IOP 22 mm Hg. Measurement of best corrected visual acuity and IOP, RAPD assessment, slit lamp examination, funduscopy, fundus photography, retinal map thickness analysis with OCT (Stratus Zeiss instruments version 3, Germany), and FA were performed at presentation. All patients were informed about the procedure and consents were obtained. All injections were performed under sterile condition in the operating room. After topical anesthesia with tetracaine 0.5% and instillation of povidineiodine 5% in cul-de-sac, the eyes were draped. A sterile speculum was placed. An anterior chamber paracentesis (0.1 ml) was performed. The drug (4 mg triamcinolone acetonide in 0.1 ml) was injected in the vitreous cavity inferotemporally through pars plana with a 27-gauge needle on a 1 ml tuberculin syringe. Then the Speculum was removed. Eyes were patched with gentamicin ointment. Then the patients were instructed to instill ciprofloxacine 0.3% ophthalmic drop for one week. Patients were re-examined at 1 day, 1 week, 1, 3, 6, and 9 months after injection. At 3 months follow up, fundus photography and retinal map thickness analysis were also performed. The main outcome measures were BCVA which was determined by the Early Treatment Diabetic Retinopathy Study chart and calculated as logmar and 1-mm central macular thickness that measured with OCT. Paired-sample t-test and Pearson correlation analysis were used for statistical analysis. A p value of < 0.05 was considered significant. Results Between September 2004 and November 2005, 25 eyes of 25 patients with nonischemic CRVO were enrolled in this study. The mean age of the patients was 57.04±16.76 years
3 (range years) at injection time. There were 7 females and 18 males. All eyes underwent single (4 mg in 0.1 ml) intravitreal triamcinolone acetonide injection. The mean duration from onset of symptoms to treatment was 83.72±57.60 days (minimum 30 and maximum 120 days). Four patients had diabetes mellitus and one of them also had a history of cerebrovascular accident. Seven patients had hypertension, and 2 patients had history of myocardial infarction while only 2 patients were heavy smokers. The mean BCVA at presentation was 1.34±0.71 logmar ( 20 / 400 ), which significantly improved to 0.67±0.42 logmar ( 20 / 100 ), (P=0.000), 0.61±0.42 logmar ( 20 / 80 ), (P=0.000), 0.90±0.62 logmar ( 20 / 160 ), (P=0.004) at 1, 3 and 6 months respectively, but was decreased to 1.43±0.76 logmar ( 20 / 600 ), (P=0.188) in 16 of 25 eyes that followed-up for 9 months. In 12 of 16 eyes without development or progression of cataract at 9 months of follow up VA was decreased to 1.33±0.82 logmar ( 20 / 400 ), (P=0.191). In 2 of 25 eyes, BCVA was decreased from baseline at 1, 3, and 6 months of follow-up, and also 1 mm central macular thickness was increased at 3 months after injection. One eye progressed to ischemic type CRVO with development of epiretinal membrane. Even though, that eye was candidate for deep pars plana vitrectomy and membrane peeling but the patient did not consent to it. A 42.85% reduction in mean baseline 1 mm central macular thickness (634.36± µm [range: µm]) to (362.56± µm [range: µm]) was observed at 3 months (P=0.000). Ten eyes (40%) developed intraocular pressure (IOP) values of 22 mm Hg or higher. Elevation of IOP occurred between 1 week and 1 month after treatment which was assumed to be a side effect of triamcinolone acetonide. All of these eyes required topical IOP lowering medications (1-3 drugs). In One eye, IOP was not controlled with medications and had undergone trabeculectomy but in 9 eyes IOP was controlled despite discontinuation of antiglaucoma medications at the final visit. The duration of retinal vein occlusion did not correlate significantly with 6 month visual acuity gain (P=0.722). There was no significant correlation between baseline 1 mm central macular thickness and visual acuity gain at 6 months (25 eyes) (P=0.253), and visual change at 9 months (16 eyes) (P=0.89). There was a significant correlation between the change in baseline 1 mm central macular thickness and the corresponding visual acuity gain (P=0.049) at 3 months follow-up. Also there was a significant correlation between the baseline VA with VA gain at 3 and 6 months (P=0.000), (P=0.001) respectively. All eyes were phakic. Six eyes showed development or progression of cataract during follow up of which one underwent cataract extraction. In our study no major complication such as retinal detachment, vitreous hemorrhage or endophthalmitis was seen. Discussion Macular edema is a common cause of visual loss after central retinal vein occlusion. 2,3 The Central Vein Occlusion Study Group (CVOSG) did not find any significant difference in VA between laser-treated and untreated eyes with macular edema due to CRVO at any point during follow-up. 18 Various other treatment modalities have been investigated but none have proven to be consistently successful Several case series studies have suggested that intravitreal triamcinolone acetonide may be effective in the treatment of macular edema which is a common cause of decreased VA due to CRVO. 11,13-17,22-24 The mechanism of action of corticosteroid to decrease macular edema in CRVO is unknown. Triamcinolone has been shown experimentally to reduce the breakdown of blood-retina barrier. 25 After single injection of 4 mg triamcinolone acetonide, we observed, central macular thickness reduction by 42.85% of its pre injection value. Williamson et al 15 reported macular thickness reduction by 32% (by 2 mg intravitreal triamcinolone injection) and Tewari et al 16 reported 75% reduction of macular thickness (by 4 mg intravitreal triamcinolone) at 3 months follow-up. In our study the central macular thickness was increased in 2 eyes. Progression to ischemic type and epiretinal membrane formation occurred in one of these eyes. And 8
4 the exact mechanism of increased macular thickness in the other eye was unknown. VA improvement was occurred at 1week to 1 month after injection and remained stable for 3-6 months. This is in agreement with the findings of other studies. 12,14-17,24 VA decreased in 16 eyes at the follow up of 9 months. The overall deterioration of VA in our patients after 6 months is possibly due to recurrence of macular edema after wash out of triamcinolone acetonide from the vitreous cavity. However we can not rule out the possibility of the cataract being partially responsible for long term VA deterioration. In our study, visual improvement of 0.3 logmar was observed in 84%, 92%, 68%, of all 25 eyes at 1, 3, 6 months, respectively. Although this improvement was observed in only 6% of 16 eyes at 9 months of follow up. The natural course study of eyes with perfused CRVO demonstrated that 47% of eyes with initial visual acuity of 20/50 or worse would have final visual acuity (at 3 years) of 20 / 250 or worse. 1 In our study visual acuity decreased to 20 / 250 or worse in 20.80% and 60.25% of eyes at 6 and 9 months of followup, respectively. The higher rate of visual acuity deterioration in our study in addition to natural course of disease may be related to development or progression of cataract or IOP rises in eyes that intravitreal triamcinolone acetonide were injected. In this study we had no significant complication such as retinal detachment, vitreous hemorrhage or endophthalmitis, but the common complication was steroid induced IOP elevation. The rate of elevated IOP was still 40% despite exclusion of patients with glaucoma or ocular hypertension ( 22 mm Hg). Other studies reported IOP elevation of 50%, 61.5%, 46% and therefore the rate of IOP elevation, underscores the need for careful follow-up. In most cases, the elevated pressure is controlled successfully with topical anti- glaucoma drugs, but recalcitrant cases may require glaucoma filtering surgery. Çekiç et al 14 reported 2 of their 24 patients with glaucoma required trabeculectomy. A recent report documented a case of intractable glaucoma after 4 mg intravitreal triamcinolone in an eye with CRVO, which required removal of the depot corticosteroid by pars plana vitrectomy combined with trabeculectomy. 26 In our study only 1 eye underwent trabeculectomy. CVOSG noted the rate of conversion to ischemia to be 15% in the first 4 months and 34% after 3 years. 1 Williamson et al 15 reported that 2 of 18 of their patients were converted to ischemic CRVO. Hayreh et al 27 reported conversion of nonischemic to ischemic CRVO at 6 months and 18 months to be 13.2% and 18.6%, respectively in persons 65 years of age or older. The rates of conversion however in persons years were 6.7% and 8.1%, respectively at 6 months and 18 months of follow up. One eye in our study converted to ischemic CRVO. In this patient triamcinolone was injected after 45 days from onset of symptoms. Another eye showed an increase in macular edema and a decrease in VA after injection but did not convert to ischemic type. The exact mechanism of increase in macular edema in this patient is unknown. Development or progression of cataract has been described in patients after triamcinolone injection. Park et al 13 observed cataract progression in 1 eye. Krepler et al 17 observed beginning of cataract in 5 eyes of 11 phakic patients, but none of them required cataract extraction. Çekiç et al 14 reported 8 (50%) of 16 phakic eyes showed progression to dense cataract and 2 eyes underwent cataract surgery. In our study, 6 eyes (24%) developed or progressed to cataract, in whom, one eye underwent cataract extraction. We expect that the rate of cataract progression may increase with longer follow up. Endophthalmitis (sterile or bacterial) is a major post injection complication. Moshfeghi et al 28 reported the rate of acute infectious postoperative endophthalmitis to be 0.87%. Sterile endophthalmitis is presumed to be an inflammatory reaction to some chemicals used in formulation 29 and pseudohypopyon is reported after intravitreal triamcinolone injection. 30,31 In our study no endophthalmitis was observed and no neovascularization occurred in the treated eyes. We observed significant correlation between baseline VA and VA gain at 6 months. We also observed significant correlation between VA gain and central macular thickness change at 3 months. No significant correlation was observed between mean baseline central macular thickness and 9
5 VA gain at 6 months. There was no significant correlation between the duration of CRVO symptoms at presentation and VA improvement at 6 months of follow-up. However no significant correlations were observed between the age and VA improvement and between the age and central macular thickness change at 3 months of follow up. Conclusion In conclusion, intravitreal triamcinolone acetonide can reduce macular edema and improve VA in nonischemic CRVO at least in a short term (3-6months). Despite the References potential of triamcinolone to improve VA, this treatment should be used judiciously because of numerous potential complications and lack of the long term observation. Major limitation of this study, include, lack of control group to clarify the risks and benefits of intravitreal triamcinolone and long term follow-up. Due to the absence of serial OCT during observation, identification of exact time of recurrence of macular edema was impossible. Acknowledgment This study was supported by the grant 132/10593 from Tehran University of Medical, Eye Research Center. 1. Natural history and clinical management of central retinal vein occlusion. The central vein occlusion study group. Arch Ophthalmol 1997; 115: Nussenblatt RB, Kaufman SC, Palastine AG, Daris MD, Ferris FL. Macular thickness and visual acuity measurement in patient with cystoid macular edema. Ophthalmology 1987; 94: Klein ML, Finkelstein D. Macular grid photocoagulation for macular edema in central retinal vein occlusion. Arch Ophthalmol 1989; 107: Green WR, Chan C, Hutchins GM, Terry J. Central retinal vein occlusion: A prospective histopathologic study of 29 eyes in 28 cases. Trans Am Ophthalmol Soc 1981; 79: Galcet Bernard A, Coscas G, Chabanel A, Zourdani A, Lelong F, Samama MM. Prognostic factors for retinal vein occlusion. A prspective study of 175 cases. Ophthalmology 1996; 103: Pe,er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Vascular endothelial growth factor up regulation in human central vein occlusion. Ophthalmology 1998; 105: Jonas JB, Hayler JK, Sofker A, Panda-Jonas S. Regression of neovascular iris vessels by intravitreal injection of crystalline cortisone. J Glaucoma 2001; 10: Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, et al. intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002; 109: Convway MD, Canakis C, Livir-Rallatos C, Peyman GA. Intravitreal triamcinolone acetonide refractory chronic pseudophakic cystoid macular edema. J Cataract Refract Surg 2003; 29: Funatsu H, Yamashita H, Noma H, Mimura T, Hori S. increased level of vascular endothelial growth factor and iterleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol 2002; 133: Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002; 240: Ip M, Kahana A, Altaweel M. Treatment of central retinal vein occlusion with triamcinolone acetonide: an optical coherence tomography. Semin Ophthalmol 2003; 18: Park CH, Jaffe GJ, Fekrat S. Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol 2003; 136: çekiç O, Chang S, Tseng J J, Weissman H, Del Prior LV, Schiff WM. intravitreal triamcinolone treatment for mcular edema associated with centrl retinal vein occlusion and hemiretinal vein occlusion. Retina 2005; 25:
6 15. Williamson T H., O,Donnell A. Intravitreal triamcinolone acetonide for cystoid macular edema in nonischemic central retinal vein occlusion. Am J Ophthalmol 2005; 139: Tewari H.K, Sony P, Chawwla R, Garg S.P, Venkatesh P.Prospective evaluation of intravitreal triamcinolone acetonide injection in macular edema associated with retinal vascular disorders Eur J Ophthalmol 2005;15: Krepler K, Ergun E, Sacu S, Richter-Muksch S, Wagner J, Stur M, et al. Intravitreal triamcinolone acetonide in patient with macular oedema due to central retinal vein occlusion. Acta Ophthalmol Scand 2005; 83: Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The central vein occlusion study group. Ophthalmology 1995; 102: Lit ES, Tsilimbaris M, Gotzaridis EV, D,Amico DJ. Lamina puncture pars plana optic disc surgery for central vein occlusion. Arch Ophthalmol 2002; 120: Weiss J, Treatment of central retinal vein occlusion by injection of tissue plasmin activator into a retinal vein. Am J Ophthalmol 1988; 120: MC Alister IL, Constable IJ. Laser induced chorioretinal anastomosis for treatment of nonischemic central retinal vein occlusion. Arch Ophthalmol 1995; 113: IP MS, Gottlieb J, Kahana A, Scott IU, Altaweel M, Blodi BA, et al. Intravitreal triamcinolone for treatment of macular edema associated with central retinal vein occlusion. Arch Ophthalmol 2004; 122: Greenberg PB, Martidis A, Rogers AH, Ducker JS, Reichel E. intravitreal triamcinolone acetonide for macular oedema due to central vein occlusion. Br J Ophthalmol 2002; 86: Bashshur Z F, Ma,luf R N, Allam S, Jurdi F A, Haddad R S, Noureddin B N. intravitreal triamcinolone for the management of macular edema due to nonischemic central vein occlusion. Arch Ophthalmol 2004; 122: Wilson CA, Berkowitz BA, Sato Y, Ando N, Handa JT, de juane E Jr. Treatment with intravitreal steroid reduced blood-retina barrier breakdown due to retinal photocoagulation. Arch Ophthalmol 1992; 110: Kaushik S, Gupta V, Gupta A, Dogra Ram M, Singh R. Intractable glaucoma following intravitreal triamcinolone in central retinal occlusion. Am J Ophthalmol 2004; 137: Hayreh SS, Zimmerman MB, Podhajsky P. Incidence of various type of retinal vein occlusion And their recurrence and demographic characteristics. Am J Ophthalmol 1994; 117(4): Moshfeghi DM, Kaiser PK, Scott IU, Sears JE, Benz M, Sinessterra JP, et al. Acute endopthalmitis following intravitreal triamcinolone injection. Am J Ophthalmol 2003; 136: Roth DB, ChiehJ, Spirn MJ, Green SN, Yarian DL, Chaudhry NA. Non infectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 2003;121: Sutter FKP, Gillies MC. Pseudoendophthalmitis after intravitreal injection of triamcinolone. Br J Ophthalmol 2003; 87: Sharma M.C, Lai W.W, Shapiro M.J. Pseudoendophthalmitis following intravitreal triamcinolone acetonide injection. Cornea 2004; 23:
CLINICAL SCIENCES. Intravitreal Triamcinolone for the Treatment of Macular Edema Associated With Central Retinal Vein Occlusion
CLINICAL SCIENCES Intravitreal Triamcinolone for the Treatment of Macular Edema Associated With Central Retinal Vein Occlusion Michael S. Ip, MD; Justin L. Gottlieb, MD; Alon Kahana, MD, PhD; Ingrid U.
More informationEFFICACY OF INTRAVITREAL TRIAMCINOLONE ACETONIDE FOR THE TREATMENT OF DIABETIC MACULAR EDEMA
Basrah Journal Of Surgery EFFICACY OF INTRAVITREAL TRIAMCINOLONE ACETONIDE FOR THE TREATMENT OF DIABETIC MACULAR EDEMA Salah Zuhair Abed Al-Asadi MB,ChB, FICMS, Lecturer, Department of Surgery, College
More informationA retrospective nonrandomized study was conducted at 3
Department of Ophthalmology, Kangbuk Samsung Hospital, Sungkyunkwan University College of Medicine 1, Seoul, Korea Hangil Eye Hospital 2, Incheon, Korea Seoul National University Bundang Hospital 3, Seongnam,
More informationROLE OF LASER PHOTOCOAGULATION VERSUS INTRAVITREAL TRIAMCINOLONE ACETONIDE IN ANGIOGRAPHIC MACULAR EDEMA IN DIABETES MELLITUS
ORIGINAL ARTICLE ROLE OF LASER PHOTOCOAGULATION VERSUS INTRAVITREAL TRIAMCINOLONE ACETONIDE IN ANGIOGRAPHIC MACULAR EDEMA IN DIABETES MELLITUS Aggarwal Somesh VP 1, Shah Sonali N 2, Bharwada Rekha M 3,
More informationOCCLUSIVE VASCULAR DISORDERS OF THE RETINA
OCCLUSIVE VASCULAR DISORDERS OF THE RETINA Learning outcomes By the end of this lecture the students would be able to Classify occlusive vascular disorders (OVD) of the retina. Correlate the clinical features
More informationIntravitreal versus Posterior Subtenon Injection of Triamcinolone Acetonide for Diabetic Macular Edema
Intravitreal versus Posterior Subtenon Injection of Triamcinolone Acetonide for Diabetic Macular Edema Young Jae Choi, MD, In Kyung Oh, MD, Jae Ryung Oh, MD, PhD, Kuhl Huh, MD, PhD Department of Ophthalmology,
More informationCOMPARISON OF INTRAVITREAL TRIAMCINOLONE INJECTION VS LASER PHOTOCOAGULATION IN ANGIOGRAPHIC MACULAR EDEMA IN DIABETIC RETINOPATHY
Original Article COMPARISON OF INTRAVITREAL TRIAMCINOLONE INJECTION VS LASER PHOTOCOAGULATION IN ANGIOGRAPHIC MACULAR EDEMA IN DIABETIC RETINOPATHY Aggarwal Somesh V 1, Shah Sonali N 2, Bharwada Rekha
More informationINTRAVITREAL TRIAMCINOLONE
CLINICAL SCIENCES Predictive Factors for Visual Acuity After Intravitreal Triamcinolone Treatment for Diabetic Macular Edema Jost B. Jonas, MD; Peter Martus, PhD; Robert F. Degenring, MD; Ingrid Kreissig,
More informationThe Effect of Posterior versus Anterior Subtenon Injection of Triamcinolone on Intraocular Pressure in Eyes with Retinal Vein Occlusion
The Effect of Posterior versus Anterior Subtenon Injection of Triamcinolone on Intraocular Pressure in Eyes with Retinal Vein Occlusion Hamid Fesharaki, MD 1 Farzan Kianersi, MD 1 Hamidreza Riazi, MD 2
More informationVascular Disease Ocular Manifestations of Systemic Hypertension
Vascular Disease Ocular Manifestations of Systemic Hypertension Maynard L. Pohl, OD, FAAO Pacific Cataract & Laser Institute 10500 NE 8 th Street, Suite 1650 Bellevue, WA 98004 USA 425-462-7664 Cerebrovascular
More informationDIABETIC MACULAR edema
CLINICAL SCIENCES Intravitreal Injection of Triamcinolone for Diffuse Diabetic Macular Edema Jost B. Jonas, MD; Ingrid Kreissig, MD; Antje Söfker, MD; Robert F. Degenring, MD Objective: To evaluate the
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article A Multivariate Analysis of Intravitreal Injection of Anti-VEGF Bevacizumab in the Treatment
More informationEFFECTIVENESS OF RADIAL OPTIC NEUROTOMY FOR ISCHEMIC CENTRAL RETINAL VEIN OCCLUSION ABSTRACT
ORIGINAL ARTICLE EFFECTIVENESS OF RADIAL OPTIC NEUROTOMY FOR ISCHEMIC CENTRAL RETINAL VEIN OCCLUSION Mir Ali Shah 1, Faisal Nawaz 2, Adnan Alam 3, Bilal Khan 4 1-4 Department of Ophthalmology, Lady Reading
More informationNeovascular Glaucoma Associated with Cilioretinal Artery Occlusion Combined with Perfused Central Retinal Vein Occlusion
Neovascular Glaucoma Associated with Cilioretinal Artery Occlusion Combined with Perfused Central Retinal Vein Occlusion Man-Seong Seo,* Jae-Moon Woo* and Jeong-Jin Seo *Department of Ophthalmology, Chonnam
More informationEfficacy of intravitreal bevacizumab (Avastin TM ) for shortterm treatment of diabetic macular edema
111 ORIGINAL Efficacy of intravitreal bevacizumab (Avastin TM ) for shortterm treatment of diabetic macular edema Toshihiko Nagasawa, Takeshi Naito, Shingo Matsushita, Hiroyuki Sato, Takashi Katome, and
More informationResearch Article Long-Term Outcome after Vitrectomy for Macular Edema with Retinal Vein Occlusion Dividing into the Occlusion Site
Hindawi Publishing Corporation Journal of Ophthalmology Volume 2014, Article ID 198782, 6 pages http://dx.doi.org/10.1155/2014/198782 Research Article Long-Term Outcome after Vitrectomy for Macular Edema
More informationThe use of a high-intensity laser to create an anastomotic
Case Report 866 Laser Chorioretinal Venous Anastomosis for Progressive Nonischemic Central Retinal Vein Occlusion Chih-Hsin Chen, MD; Chien-Hsiung Lai 1, MD; Hsi-Kung Kuo, MD The use of high or medium-intensity
More informationDiabetic retinopathy (DR) progressively
FOCUS ON DIABETIC MACULAR EDEMA * Frederick L. Ferris III, MD ABSTRACT The current state of treatment for diabetic macular edema (DME) is focused on slowing the rate of vision loss through assessment of
More informationDiagnosis and treatment of diabetic retinopathy. Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City
Diagnosis and treatment of diabetic retinopathy Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City Disclosures Consulted for Novo Nordisk 2017,2018. Will be discussing
More informationIntravitreal triamcinolone acetonide injection as primary treatment for diabetic macular edema
European Journal of Ophthalmology / Vol. 14 no. 6, 2004 / pp. 543-549 Intravitreal triamcinolone acetonide injection as primary treatment for diabetic macular edema A. ÖZKIRIS 1, C. EVEREKLIOGLU 1, K.
More informationComparison of the Short-Term Effects of Intravitreal Triamcinolone Acetonide and Bevacizumab Injection for Diabetic Macular Edema
pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2011;25(3):156-160 DOI: 10.3341/kjo.2011.25.3.156 Original Article Comparison of the Short-Term Effects of Intravitreal Triamcinolone Acetonide and
More informationEvaluation of Changes of Macular Thickness in Diabetic Retinopathy after Cataract Surgery
pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2011;25(4):238-242 DOI: 10.3341/kjo.2011.25.4.238 Evaluation of Changes of Macular Thickness in Diabetic Retinopathy after Cataract Surgery Original
More informationEfficacy of combined intravitreal bevacizumab and triamcinolone for branch retinal vein occlusion
AOP*** 1 Original Article Efficacy of combined intravitreal bevacizumab and triamcinolone for branch retinal vein occlusion Rasha I Ali1, Kapil G Kapoor 1,2, Adeel N Khan 1, Syed K Gibran 1 Purpose: To
More informationBevacizumab for Macular Edema in Central Retinal Vein Occlusion: A Prospective, Randomized, Double-Masked Clinical Study
Bevacizumab for Macular Edema in Central Retinal Vein Occlusion: A Prospective, Randomized, Double-Masked Clinical Study David L.J. Epstein, MD, Peep V. Algvere, MD, PhD, Gunvor von Wendt, MD, PhD, Stefan
More informationIntravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema due to central retinal vein occlusion
(2009) 23, 2215 2222 & 2009 Macmillan Publishers Limited All rights reserved 0950-222X/09 $32.00 www.nature.com/eye Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema due
More informationEfficacy of Intravitreal Triamcinolone Acetonide for Eyes with Postvitrectomy Diabetic Vitreous Hemorrhage
Korean Journal of Ophthalmology 21(4):208-212, 2007 DOI : 10.3341/kjo.2007.21.4.208 Efficacy of Intravitreal Triamcinolone Acetonide for Eyes with Postvitrectomy Diabetic Vitreous Hemorrhage Sun Young
More informationAndrew J. Barkmeier, MD; Benjamin P. Nicholson, MA; Levent Akduman, MD
c l i n i c a l s c i e n c e Effectiveness of Laser Photocoagulation in Clinically Significant Macular Edema With Focal Versus Diffuse Parafoveal Thickening on Optical Coherence Tomography Andrew J. Barkmeier,
More informationMoncef Khairallah, MD
Moncef Khairallah, MD Department of Ophthalmology, Fattouma Bourguiba University Hospital Faculty of Medicine, University of Monastir Monastir, Tunisia INTRODUCTION IU: anatomic form of uveitis involving
More informationComparison of the Effect of Adjuvant 5-Fluorouracil, Low Molecular Weight Heparin and Daunomycin in
Comparison of the Effect of Adjuvant 5-Fluorouracil, Low Molecular Weight Heparin and Daunomycin in Combination with Triamcinolone during Vitrectomy in Advanced Retinal Detachment Ahmad Mirshahi, MD, 1
More informationRetinal Vein Occlusion (RVO) Treatment pathway- Northeast England. Retinal Vein Occlusion (RVO) with Macular oedema (MO)
Retinal Vein Occlusion (RVO) Treatment pathway- Northeast England (Royal Victoria Infirmary, Sunderland Eye Infirmary, James Cook University Hospital, Darlington Memorial Hospital, University Hospital
More informationResearch Article http://www.alliedacademies.org/clinical-ophthalmology-and-vision-science/ A 2-year retrospective study of the treatment of retinal vein occlusion with dexamethasone 0.7 mg intravitreal
More informationPOSTERIOR SUBTENON INJECTION OF TRIAMCINALONE ACETONIDE FOR CYSTOID DIABETIC MACULAR EDEMA
POSTERIOR SUBTENON INJECTION OF TRIAMCINALONE ACETONIDE FOR CYSTOID DIABETIC MACULAR EDEMA Basel T. Ba arah MD, PhD*, Farid H. Al-Zawaideh MD*, Issam M. Al-Bataineh MD* ABSTRACT Objectives: To assess the
More informationNatural Short-term Course of Recurrent Macular Edema Following Intravitreal Bevacizumab Therapy in Branch Retinal Vein Occlusion
pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2017;31(2):95-101 https://doi.org/10.3341/kjo.2017.31.2.95 Original Article Natural Short-term Course of Recurrent Macular Edema Following Intravitreal
More informationVitrectomy for Diabetic Cystoid Macular Edema
Vitrectomy for Diabetic Cystoid Macular Edema Yukihiro Sato, Zeon Lee and Hiroyuki Shimada Department of Ophthalmology, Nihon University School of Medicine, Tokyo, Japan Purpose: We evaluated visual outcomes
More informationThe Common Clinical Competency Framework for Non-medical Ophthalmic Healthcare Professionals in Secondary Care
The Common Clinical Competency Framework for Non-medical Ophthalmic Healthcare Professionals in Secondary Care Medical Retina November 2016 Association of Health Professions in Ophthalmology General basic
More informationClinically Significant Macular Edema (CSME)
Clinically Significant Macular Edema (CSME) 1 Clinically Significant Macular Edema (CSME) Sadrina T. Shaw OMT I Student July 26, 2014 Advisor: Dr. Uwaydat Clinically Significant Macular Edema (CSME) 2
More informationmeasure of your overall performance. An isolated glucose test is helpful to let you know what your sugar level is at one moment, but it doesn t tell you whether or not your diabetes is under adequate control
More informationDexamethasone Intravitreal Implant Rescue Treatment for Bevacizumab Refractory Macular Edema Secondary to Branch Retinal Vein Occlusion
pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2017;31(2):108-114 https://doi.org/10.3341/kjo.2017.31.2.108 Original Article Dexamethasone Intravitreal Implant Rescue Treatment for Bevacizumab Refractory
More informationStudy of clinical significance of optical coherence tomography in diagnosis & management of diabetic macular edema
Original Research Article Study of clinical significance of optical coherence tomography in diagnosis & management of diabetic macular edema Neha Kantilal Desai 1,*, Somesh Vedprakash Aggarwal 2, Sonali
More informationYoshiro Minami 1*, Taiji Nagaoka 2, Akihiro Ishibazawa 1,2 and Akitoshi Yoshida 2
Minami et al. BMC Ophthalmology (2017) 17:90 DOI 10.1186/s12886-017-0485-4 RESEARCH ARTICLE Open Access Correlation between short- and long-term effects of intravitreal ranibizumab therapy on macular edema
More informationTuberous sclerosis presenting as atypical aggressive retinal astrocytoma with proliferative retinopathy and vitreous haemorrhage
Case Report Brunei Int Med J. 2015; 11 (1): 49-53 Tuberous sclerosis presenting as atypical aggressive retinal astrocytoma with proliferative retinopathy and vitreous haemorrhage Pui Ling TANG and Mae-Lynn
More informationClinical Case Presentation. Branch Retinal Vein Occlusion. Sarita M. Registered Nurse Whangarei Base Hospital
Clinical Case Presentation on Branch Retinal Vein Occlusion Sarita M. Registered Nurse Whangarei Base Hospital Introduction Case Study Pathogenesis Clinical Features Investigations Treatment Follow-up
More informationIntravitreal bevacizumab for pediatric exudative retinal diseases
Saudi Journal of Ophthalmology (2011) 25, 193 197 King Saud University Saudi Journal of Ophthalmology www.saudiophthaljournal.com www.ksu.edu.sa www.sciencedirect.com ORIGINAL ARTICLE Intravitreal bevacizumab
More informationOriginal Article. Authors
Original Article APMC-303 Efficacy of Intra-Vitreal Bevacizumab Combined with Phaco- Emulsification in the Prophylaxis of Macular Edema in Patients with Non-Proliferative Diabetic Retinopathy Muhammad
More informationEfficacy and safety of Pro Re Nata regimen without loading dose ranibizumab injections in retinal vein occlusion
Open Access Original Article Efficacy and safety of Pro Re Nata regimen without loading dose ranibizumab injections in retinal vein occlusion Erkan Unsal 1, Kadir Eltutar 2, Pınar Sultan 3, Hulya Gungel
More informationRecalcitrant Diabetic Macular Oedema: Therapeutic Options
December 2007 A. Giridhar et al. - Recalcitrant DME 451 CONSULTATION S E C T I O N Recalcitrant Diabetic Macular Oedema: Therapeutic Options Dr. Cyrus M Shroff 1, Dr. N S Muralidhar 2, Dr. R Narayanan
More informationMacular edema (ME) is the most common
MANAGEMENT OF RETINAL VEIN OCCLUSIONS * Peter A. Campochiaro, MD ABSTRACT Macular edema (ME) is the most common cause of reduced vision in patients with retinal vein occlusions (RVOs). The primary cause
More informationPosterior Subtenon Triamcinolone Acetonide in Gas-filled Eyes as an Adjunctive Treatment for Complicated Proliferative Diabetic Retinopathy
pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2013;27(1):28-33 http://dx.doi.org/10.3341/kjo.2013.27.1.28 Original Article Posterior Subtenon Triamcinolone Acetonide in Gas-filled Eyes as an Adjunctive
More informationSystematic literature review of treatments for management of complications of ischemic central retinal vein occlusion
Bradshaw et al. BMC Ophthalmology (2016) 16:104 DOI 10.1186/s12886-016-0282-5 RESEARCH ARTICLE Open Access Systematic literature review of treatments for management of complications of ischemic central
More informationDiabetic Retinopathy
Diabetic Retinopathy Diabetes can be classified into type 1 diabetes mellitus and type 2 diabetes mellitus, formerly known as insulin-dependent diabetes mellitus, and non-insulin diabetes mellitus, respectively.
More informationPars Plana Vitrectomy for Retinal Detachments Associated with Chorioretinal Coloboma
Pars Plana Vitrectomy for Retinal Detachments Associated with Chorioretinal Coloboma Mohammad Riazi-Esfahani, MD 1,2 Mehdi Behnia, MD 2 Hooshang Faghihi, MD 1 Zahra Aalami-Harandi, MD 1 Reza Karkhaneh,
More informationResearch Article http://www.alliedacademies.org/clinical-ophthalmology-and-vision-science/ The trial: A pilot study to assess the efficacy, durability, and safety of combination ranibizumab + peripheral
More informationClinical Study Choroidal Thickness in Eyes with Unilateral Ocular Ischemic Syndrome
Hindawi Publishing Corporation Journal of Ophthalmology Volume 215, Article ID 62372, 5 pages http://dx.doi.org/1.1155/215/62372 Clinical Study Choroidal Thickness in Eyes with Unilateral Ocular Ischemic
More informationClinical Study Evaluation of Peripapillary Nerve Fiber Layer after Dexamethasone Implantation (Ozurdex) in Branch Retinal Vein Occlusions
Ophthalmology Volume 2016, Article ID 2050796, 4 pages http://dx.doi.org/10.1155/2016/2050796 Clinical Study Evaluation of Peripapillary Nerve Fiber Layer after Dexamethasone Implantation (Ozurdex) in
More informationFA Conference. Lara Rosenwasser Newman, M.D. 10/2/14 University of Louisville Department of Ophthalmology and Visual Sciences
FA Conference Lara Rosenwasser Newman, M.D. 10/2/14 University of Louisville Department of Ophthalmology and Visual Sciences Patient Presentation CC: (sent by optometrist) Blurry/foggy vision HPI: 62 yo
More informationRetinal vein occlusion (RVO) is a vascular disease
INTRAVITREAL RANIBIZUMAB FOR RETINAL VEIN OCCLUSION THROUGH 1 YEAR IN CLINICAL PRACTICE TROELS BRYNSKOV, MD,* HENRIK KEMP, MD,* TORBEN L. SØRENSEN, MD, DMSC* Purpose: To evaluate the efficacy and safety
More informationClinical Outcomes After Intravitreal Bevacizumab Injection for Diabetic Macular Edema
Original Article Clinical Outcomes After Intravitreal Bevacizumab Injection for Diabetic Macular Edema Karen Joyce G. Castro, MD, Marie Joan V. Loy, MD International Eye Institute St. Luke s Medical Center
More informationCase Report Macular Oedema Related to Idiopathic Macular Telangiectasia Type 1 Treated with Dexamethasone Intravitreal Implant (Ozurdex)
Case Reports in Ophthalmological Medicine, Article ID 231913, 5 pages http://dx.doi.org/10.1155/2014/231913 Case Report Macular Oedema Related to Idiopathic Macular Telangiectasia Type 1 Treated with Dexamethasone
More informationComparison of Ranibizumab and Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion
pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2017;31(3):209-216 https://doi.org/10.3341/kjo.2015.0158 Original Article Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated with
More informationPreliminary report on effect of retinal panphotocoagulation on rubeosis iridis and
British Journal of Ophthalmology, 1977, 61, 278-284 Preliminary report on effect of retinal panphotocoagulation on rubeosis iridis and neovascular glaucoma LEILA LAATIKAINEN From Moorfields Eye Hospital,
More informationOptical Coherence Tomograpic Features in Idiopathic Retinitis, Vasculitis, Aneurysms and Neuroretinitis (IRVAN)
Columbia International Publishing Journal of Ophthalmic Research (2014) Research Article Optical Coherence Tomograpic Features in Idiopathic Retinitis, Vasculitis, Aneurysms and Neuroretinitis (IRVAN)
More informationChristina L. Ryu, 1 Adrian Elfersy, 1 Uday Desai, 1 Thomas Hessburg, 1 Paul Edwards, 1 and Hua Gao 1,2. 1. Introduction
Ophthalmology, Article ID 317694, 6 pages http://dx.doi.org/10.1155/2014/317694 Research Article The Effect of Antivascular Endothelial Growth Factor Therapy on the Development of Neovascular Glaucoma
More informationVISUAL OUTCOME IN DIABETIC MACULAR EDEMA AFTER GRID LASER TREATMENT
The Professional Medical Journal DOI: 10.17957/TPMJ/16.2856 ORIGINAL PROF-2856 VISUAL OUTCOME IN DIABETIC MACULAR EDEMA AFTER GRID LASER TREATMENT 1. MBBS.FCPS Assistant Professor Ophthalmology Independent
More informationVitrectomy in vitreomacular traction syndrome evaluated by ocular coherence tomography (OCT) retinal mapping.
Vitrectomy in vitreomacular traction syndrome evaluated by ocular coherence tomography (OCT) retinal mapping. Larsson, Jörgen Published in: Acta Ophthalmologica Scandinavica DOI: 10.1111/j.1600-0420.2004.00344.x
More informationPars Plana Vitrectomy and Internal Limiting Membrane Peeling for Macular Oedema Secondary to Retinal Vein Occlusion: a Pilot Study
Case Series 293 Pars Plana Vitrectomy and Internal Limiting Membrane Peeling for Macular Oedema Secondary to Retinal Vein Occlusion: a Pilot Study Xiao-Ling Liang, 1* MD, PhD, Hao-Yu Chen, 1* MD, Yong-Sheng
More informationStudy of the Effect of Injection Bevacizumab through Various Routes in Neovascular Glaucoma
JOCGP Original Article Study of the Effect of Injection Bevacizumab through Various 10.5005/jp-journals-10008-1200 Routes in Neovascular Glaucoma Study of the Effect of Injection Bevacizumab through Various
More informationA Patient s Guide to Diabetic Retinopathy
Diabetic Retinopathy A Patient s Guide to Diabetic Retinopathy 840 Walnut Street, Philadelphia PA 19107 www.willseye.org Diabetic Retinopathy 1. Definition Diabetic retinopathy is a complication of diabetes
More informationIntravitreal Monotherapy with Bevacizumab and Triamcinolone Versus Combination Therapy in Recalcitiant Diabetic Macular Edema
Intravitreal Monotherapy with Bevacizumab and Triamcinolone Versus Combination Therapy in Recalcitiant Diabetic Macular Edema Meena Chakrabarti MS, DO, DNB Meena Chakrabarti MS, DO, DNB, Sonia Rani John
More informationEffects of an Intravitreal Bevacizumab Injection Combined With Panretinal Photocoagulation on High-Risk Proliferative Diabetic Retinopathy
Korean Journal of Ophthalmology 2009;23:266-272 ISSN : 1011-8942 DOI : 10.3341/kjo.2009.23.4.266 Effects of an Intravitreal Bevacizumab Injection Combined With Panretinal Photocoagulation on High-Risk
More informationCase Report Inherent Challenges in Managing Long Standing Refractory Diabetic Macular Edema
Cronicon OPEN ACCESS EC OPHTHALMOLOGY Case Report Inherent Challenges in Managing Long Standing Refractory Diabetic Macular Edema V Swetha E Jeganathan 1,2 * and Karen Madill 3 1 Department of Ophthalmology,
More informationRecurrent intraocular hemorrhage secondary to cataract wound neovascularization (Swan Syndrome)
Recurrent intraocular hemorrhage secondary to cataract wound neovascularization (Swan Syndrome) John J. Chen MD, PhD; Young H. Kwon MD, PhD August 6, 2012 Chief complaint: Recurrent vitreous hemorrhage,
More informationUpdate and review of central retinal vein occlusion Nikolas J.S. London and Gary Brown
Update and review of central retinal vein occlusion Nikolas J.S. London and Gary Brown Retina Service, Wills Eye Institute, Thomas Jefferson University, Philadelphia, Pennsylvania, USA Correspondence to
More informationE xudative age related macular degeneration is one of the
462 CLINICAL SCIENCE Intravitreal triamcinolone acetonide for exudative age related macular degeneration J B Jonas, I Kreissig, P Hugger, G Sauder, S Panda-Jonas, R Degenring... See end of article for
More informationZEISS AngioPlex OCT Angiography. Clinical Case Reports
Clinical Case Reports Proliferative Diabetic Retinopathy (PDR) Case Report 969 PROLIFERATIVE DIABETIC RETINOPATHY 1 1-year-old diabetic female presents for follow-up of proliferative diabetic retinopathy
More informationComparison of Intravitreal Injection of Bevacizumab and Triamcinolone Acetonide in the Treatment of Uveitic Macular Edema
ISSN 1735-1383 Iran. J. Immunol. June 2012, 9 (2), 136-144 Mansour Rahimi, Seyed Sahabaldin Shahrzad, Mohammad Banifatemi Comparison of Intravitreal Injection of Bevacizumab and Triamcinolone Acetonide
More informationFoveal Sensitivity and Morphology in Major and Macular Branch Retinal Vein Occlusion
Send Orders of Reprints at bspsaif@emirates.net.ae 104 The Open Ophthalmology Journal, 2012, 6, 104-109 Open Access Foveal Sensitivity and Morphology in Major and Macular Branch Retinal Vein Occlusion
More informationOff-label use of intravitreal bevacizumab in non-ischemic macular edema secondary to retinal vein obstructions
Romanian Journal of Ophthalmology, Volume 60, Issue 2, April-June 2016. pp:90-95 GENERAL ARTICLE Off-label use of intravitreal bevacizumab in non-ischemic macular edema secondary to retinal vein obstructions
More informationAbbreviated Drug Evaluation: Fluocinolone acetonide intravitreal implant (Retisert )
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationAn Update on Branch Retinal Vein Occlusion Treatment Studies. Amiee Ho, O.D. Pacific University College of Optometry
An Update on Branch Retinal Vein Occlusion Treatment Studies Amiee Ho, O.D. Pacific University College of Optometry Course Description This course focuses on current treatment options available for macular
More informationNeuropathy (NAION) and Avastin. Clinical Assembly of the AOCOO-HNS Foundation May 9, 2013
Non Arteritic Ischemic Optic Neuropathy (NAION) and Avastin Shalom Kelman, MD Clinical Assembly of the AOCOO-HNS Foundation May 9, 2013 Anterior Ischemic Optic Neuropathy Acute, painless, visual loss,
More informationANGIO OCT IMAGING OF MACULAR VASCULATURE IN DIABETIC MACULAR EDEMA BEFORE AND AFTER MACULAR SURGERY
17th EVRS Meeting September 14-17, 2017 Teatro della Pergola FLORENCE - ITALY ANGIO OCT IMAGING OF MACULAR VASCULATURE IN DIABETIC MACULAR EDEMA BEFORE AND AFTER MACULAR SURGERY G. Macrì, G. Pacelli, V.
More informationQuantitative Reduction in Central Foveal Thickness After First Anti-VEGF Injection as a Predictor of Final Outcome in BRVO Patients
Original clinical study Quantitative Reduction in Central Foveal Thickness After First Anti-VEGF Injection as a Predictor of Final Outcome in BRVO Patients Rupak Roy, MS, Kumar Saurabh, MS, Avirupa Ghose,
More informationOphthalmology Macular Pathways
Ophthalmology Macular Pathways Age related Macular Degeneration Diabetic Macular Oedema Macular Oedema secondary to Central Retinal Macular Oedema secondary to Branch Retinal CNV associated with pathological
More informationVitrectomy Combined with Intravitreal Triamcinolone Acetonide Injection and Macular Laser Photocoagulation for Nontractional Diabetic Macular Edema
pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2013;27(3):186-193 http://dx.doi.org/10.3341/kjo.2013.27.3.186 Original Article Vitrectomy Combined with Intravitreal Triamcinolone Acetonide Injection
More informationOptometric Postoperative Cataract Surgery Management
Financial Disclosures Optometric Postoperative Cataract Surgery Management David Dinh, OD Oak Cliff Eye Clinic Dallas Eye Consultants March 10, 2015 Comanagement Joint cooperation between two or more specialists
More informationPresumed Sterile Endophthalmitis After Intravitreal Triamcinolone (Kenalog) More Common and Less Benign Than We Thought?
original clinical study Presumed Sterile Endophthalmitis After Intravitreal Triamcinolone (Kenalog) More ommon and ess Benign Than We Thought? Angie H.. Fong, FOphthHK, FHKAM,* and armen K. M. han, FSEd(Ophth),
More informationTreatment for Central-Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity
Diabetic Retinopathy Clinical Research Network Treatment for Central-Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity Version 3.0 April 18, 2014 Treatment of CIDME in Eyes with Good
More informationINTRAVITREOUS BEVACIZUMAB IN THE TREATMENT OF MACUAR EDEMA FROM BRANCH RETINAL VEIN OCCLUSION AND HEMISPHERE RETINAL VEIN OCCLUSION (AN AOS THESIS)
INTRAVITREOUS BEVACIZUMAB IN THE TREATMENT OF MACUAR EDEMA FROM BRANCH RETINAL VEIN OCCLUSION AND HEMISPHERE RETINAL VEIN OCCLUSION (AN AOS THESIS) BY Gary Edd Fish MD ABSTRACT Purpose: To compare intravitreous
More informationCentral Retinal Vein Occlusion
Central Retinal Vein Occlusion Sohan Singh Hayreh, MD, MS, PhD, DSc, FRCS, FRCOphth Professor Emeritus of Ophthalmology Ocular Vascular Clinic Department of Ophthalmology and Visual Sciences The University
More informationAudit of Macular Hole Surgery, Visual Outcome Prediction on OCT Appearance of Macular Hole
International Journal of Ophthalmology & Visual Science 2017; 2(4): 93-97 http://www.sciencepublishinggroup.com/j/ijovs doi: 10.11648/j.ijovs.20170204.13 Audit of Macular Hole Surgery, Visual Outcome Prediction
More informationEarly Avastin management in acute retinal vein occlusion
Saudi Journal of Ophthalmology (2010) 24, 87 94 King Saud University Saudi Journal of Ophthalmology www.ksu.edu.sa www.sciencedirect.com ORIGINAL ARTICLE Early Avastin management in acute retinal vein
More informationScott M. Pfahler D.O. Dayton Vitreo-Retinal Associates AOCOO-HNS Palm Springs, CA 2012
Scott M. Pfahler D.O. Dayton Vitreo-Retinal Associates AOCOO-HNS Palm Springs, CA 2012 Proliferative Diabetic Retinopathy Laser Treatments Medical Treatment Surgical Treatment Diabetic Macular Edema Laser
More informationAnatomical results and complications after silicone oil removal
Romanian Journal of Ophthalmology, Volume 61, Issue 4, October-December 2017. pp:261-266 GENERAL ARTICLE Anatomical results and complications after silicone oil removal Brănişteanu Daniel Constantin* **,
More informationDiabetic and the Eye: An Introduction
Diabetic and the Eye: An Introduction Lawrence Iu FRCSEd (Ophth), FCOphthHK, FHKAM (Ophthalmology) Department of Ophthalmology, Grantham Hospital & Queen Mary Hospital Background Diabetes mellitus (DM)
More informationBevacizumab for Macular Edema in Branch and Central Retinal Vein Occlusion
RESEARCH ARTICLE Acta Medica Marisiensis 2012;58(5):329-333 Bevacizumab for Macular Edema in Branch and Central Retinal Vein Occlusion Rusu Monica-Blanka 1, Egyed ZsI 2, Maki Cristina 1 1 Ophthalmology
More informationKyungmin Lee, Heeyoung Chung, Youngsuk Park, Joonhong Sohn. HanGil Eye Hospital, Incheon, Korea
pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2014;28(4):298-305 http://dx.doi.org/10.3341/kjo.2014.28.4.298 Original Article Efficacy of Intravitreal Anti-vascular Endothelial Growth Factor or
More informationILUVIEN IN DIABETIC MACULAR ODEMA
1 ILUVIEN IN DIABETIC MACULAR ODEMA Marie Tsaloumas Consultant Ophthalmic Surgeon Queen Elizabeth Hospital, Birmingham bars conference 2104 1 2 Declaration of interest I have sat on Advisory boards for
More informationABSTRACT INTRODUCTION
DOI 10.1007/s40123-017-0114-6 ORIGINAL RESEARCH Real-World Cost Savings Demonstrated by Switching Patients with Refractory Diabetic Macular Edema to Intravitreal Fluocinolone Acetonide (Iluvien): A Retrospective
More informationMacular edema may result from a range of eye
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS Volume, Number, 215 ª Mary Ann Liebert, Inc. DOI: 1.189/jop.215.21 ORIGINAL ARTICLE Safety and Efficacy of Intravitreal Preservative-Free Triamcinolone Acetonide
More information황반부부종을동반한분지망막정맥폐쇄의치료에있어서유리체강내베바시주맙의반응을예측하는인자
Journal of Retina 2018;3(1):20-25 ORIGINAL ARTICLE pissn 2508-1926 eissn 2508-3589 황반부부종을동반한분지망막정맥폐쇄의치료에있어서유리체강내베바시주맙의반응을예측하는인자 Predictive Factors for a Favorable Response to Intravitreal Bevacizumab for
More information